Company / Accounts Receivable
KYNTRA BIO, INC. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$216.0K
FY2025
5-year range
$216.0K / $41.9M
FY2021-FY2025
Trend
-55.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has declined for 4 consecutive years, from $42M in FY2021 to $216,000 in FY2025.
Based on SEC 10-K filings.
$216,000 in FY2025 with a 5-year CAGR of -65.1%.
Declined from $13M to $216,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -76.3%
- 5-Year CAGR
- -65.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- KYNTRA BIO, INC.'s accounts receivable has declined for 4 consecutive years.
- 5-year CAGR of -65.1%, indicating a declining trend.
- In FY2025, accounts receivable decreased 55.1% year-over-year.
- Peak accounts receivable was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.33 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $216.0K | -55.1% |
| FY2024 | $481.0K | -96.2% |
| FY2023 | $12.6M | -23.0% |
| FY2022 | $16.3M | -61.1% |
| FY2021 | $41.9M | +0.0% |
| FY2020 | $41.9M | +47.2% |
| FY2019 | $28.5M | -55.3% |
| FY2018 | $63.7M | +653.5% |
| FY2017 | $8.5M | -19.1% |
| FY2016 | $10.4M | -32.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026